SLXN

2.74

3.86% -0.11

Dopo l'orario di chiusura: 2.50 -0.24 -8.76%

Silexion Therapeutics Corp (SLXN)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$2.85

Aprire:

$2.81

Volume 24 ore:

10,506

Relative Volume:

0.02

Capitalizzazione di mercato:

$2.91M

Reddito:

Utile/perdita netta:

$-11.91M

Rapporto P/E:

-0.309

EPS:

-8.8661

Flusso di cassa netto:

$-10.83M

1 W Prestazione:

+7.45%

1M Prestazione:

-41.33%

6M Prestazione:

-86.95%

1 anno Prestazione:

-97.76%

Intervallo 1D:

$2.64

$2.81

Intervallo di 1 settimana:

$2.54

$2.85

Portata 52W:

$2.31

$223.60

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Nome

Silexion Therapeutics Corp

Settore

Healthcare (1094)

Industria

Biotechnology (615)

Telefono

972-8-6286005

Indirizzo

12 ABBA HILLEL ROAD, RAMAT GAN

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-11

Ultimi documenti SEC

SLXN's Discussions on Twitter

Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SLXN Silexion Therapeutics Corp	2.74	3.03M	0	-11.91M	-10.83M	-8.8661
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie

04:02 AM

Price to earnings forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView

04:02 AM

10:01 AM

Enterprise value to EBITDA forward of Silexion Therapeutics Corp – BOATS:SLXN - TradingView

10:01 AM

Jul 03, 2026

Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN

Jul 03, 2026

Jun 28, 2026

SLXN Q1 2026 Earnings: EPS Beat Highlights Narrower-than-Expected Loss Amid Development StageFinancial Summary - dars.gov.et

Jun 28, 2026

Jun 26, 2026

Price to sales forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Price to earnings forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Jun 24, 2026

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Sahm

Jun 24, 2026

Silexion Therapeutics Warrants (SLXNW) Hold Flat at $0.03 as Range TightensComposite Profile - dars.gov.et

Jun 24, 2026

Form 13D/A Silexion Therapeutics Corp For: 23 June By Investing.com - Investing.com Australia

Jun 24, 2026

Jun 23, 2026

Silexion Therapeutics Says Germany Approves Phase 2/3 Trial of SIL204 in Pancreatic Cancer - marketscreener.com

Jun 23, 2026

Silexion Therapeutics Receives BfArM Approval to Initiate Phase 2/3 SIL204 Trial in Germany - Quiver Quantitative

Jun 23, 2026

Jun 22, 2026

[EFFECT] Silexion Therapeutics Corp SEC Filing - Stock Titan

Jun 22, 2026

SLXN Q1 2026 Earnings: Solid EPS Beat Highlights Cost Discipline Amid Pre-Revenue StageEarnings Risk Report - dars.gov.et

Jun 22, 2026

Jun 20, 2026

Silexion Therapeutics (SLXN) Slides 5.86% as Shares Approach Key Support at $2.59Oversold Bounce Ideas - dars.gov.et

Jun 20, 2026

Jun 19, 2026